Zymic Technology (ZYMIQ) Q1 2026 earnings summary

Executive summary

• Achieved international expansion through new distribution agreements and participation in major defense and security fairs in Europe.

• Shifted from preparatory work to focused execution, scaling solutions and strengthening commercial presence.

• Manufacturing consolidated in Sweden, improving quality control and cost structure.

• Key scientific milestone: Mycolyse research published in a leading biotechnology journal.

Financial highlights

• Net sales increased to SEK 835 thousand in Q1 2026, up from SEK 812 thousand in Q1 2025.

• Gross profit rose to SEK 449 thousand (Q1 2025: SEK 240 thousand), with a gross margin of 54% (Q1 2025: 30%).

• Operating loss widened to SEK -3,658 thousand (Q1 2025: SEK -2,104 thousand).

• Loss after tax was SEK -3,626 thousand (Q1 2025: SEK -2,063 thousand).

• Cash and cash equivalents at period end were SEK 522 thousand (Q1 2025: SEK 2,257 thousand).

Outlook and guidance

• Focus remains on commercial expansion, revenue growth, and strategic partnerships.

• Management is actively working to secure additional financing to support continued growth and commercialization.